Alphabet capex signals and asset rotation reshape market leadership.
US equities rotated sharply as investors reassessed capital intensity across the AI trade. Alphabet (GOOG, GOOGL) delivered a strong fourth quarter, with revenue and earnings beating expectations and Google Cloud posting nearly 48% year-over-year growth. However, management’s guidance for 2026 capital expenditure of US$175-185 billion, more than double last year at the high end, shifted investor focus from growth momentum to return visibility. Alphabet shares fell as much as 3% in extended trading following the release.
Pressure intensified across AI-linked names. Advanced Micro Devices (AMD) dropped 17.3% after issuing a weaker-than-expected first-quarter outlook, weighing on semiconductors and infrastructure plays more broadly. The Nasdaq Composite declined 1.51%, while the S&P 500 slipped 0.51%, marking its fifth negative session in six. In contrast, the Dow Jones Industrial Average rose 0.53%, supported by rotation into industrial and healthcare names such as Amgen (AMGN) and Honeywell (HON).
Cross-asset signals added context. Oil prices eased about 1% on reports of upcoming US-Iran talks, while precious metals entered a consolidation phase after sharp recent swings. The rebound and two-way positioning were visible in US-listed proxies, including VanEck Gold Miners ETF (GDX) and iShares Silver Trust (SLV).
Taken together, the rotation across equities and the stabilization in metals point to a market increasingly structuring exposure around defined scenarios and event risk, rather than broad directional bets, often through instruments such as options.
📊 Market Wrap Feb 5th 2026
🧠 Analyst Notes
💬 Market Highlights
Crown Castle Doubles Down on Towers, Cuts Costs, and Sets Up a Major Debt Paydown
Crown Castle (CCI) is accelerating its pivot into a simpler, U.S.-only tower company, pairing restructuring with tighter capital discipline. The company targeting a US$65 million annualized run-rate operating cost reduction, including a roughly 20% workforce reduction in continuing operations, as it works toward selling its small cell and fiber businesses in the first half of 2026.
The near-term outlook is weighed down by DISH-related fallout, including a US$220 million churn and the termination of the DISH agreement, but management framed 2026 organic growth of about 3.5% as a trough level that should improve from there. Balance sheet priorities are clear: after the divestiture, CCI intends to allocate proceeds toward about US$7 billion of debt repayment and about US$1 billion of share repurchases, while holding the dividend at US$4.25 per share until the payout ratio returns to the 75%-80% AFFO target range.
Alphabet Beats, but the Market Fixates on a Step-Change in 2026 AI Spending
Alphabet (GOOG, GOOGL) delivered a strong quarter on both revenue and earnings, driven by continued strength in Google Services and rapid expansion in Google Cloud. Alphabet posted Q4 revenue growth of 18% to US$113.8 billion and net income growth of 30% to US$34.46 billion, while operating margin held at 32%. The investor debate quickly shifted to 2026 capital spending, with management guiding capex to US$175–185 billion versus consensus expectations around US$119.5 billion.
Leadership tied the step-up to surging AI demand and infrastructure scaling, citing Gemini processing more than 10 billion tokens per minute via direct API usage and the Gemini App reaching about 750 million monthly active users. Cloud ended 2025 with an annual run rate above US$70 billion, but the market’s key question is whether the elevated capex trajectory can translate into durable, high-return growth.
Eli Lilly Targets Another Step-Up in 2026, with Volume Strength Partly Offset by Price Pressure
Eli Lilly (LLY) is guiding to another year of strong top-line expansion in 2026, led by volume growth across its key incretin portfolio, while acknowledging more visible price headwinds. The company expects 2026 revenue of US$80–83 billion (midpoint up 25% year over year), supported by continued demand and new launches, but with a low-to-mid teens drag from lower realized prices tied to government agreements, direct-to-patient pricing, and Medicaid dynamics.
Management highlighted expanded access efforts, including an agreement aimed at obesity medicine access through Medicare and Medicaid with US$50 per month out-of-pocket costs, and LillyDirect surpassing 1 million patients. At the same time, higher R&D and commercial investment to support launches suggests margins are likely to be relatively stable to slightly lower versus the strong Q4 2025 level, reinforcing a 2026 setup where “volume-led growth” needs to outrun price compression.
📅 Earnings Watch
With leadership rotating across equities and commodities, markets appear increasingly focused on capital discipline, return visibility, and positioning rather than headline growth alone.
What stocks are you watching today?
